A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT ID: NCT07174726

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-10
• Study Completion Date: 2030-12-15

Brief Summary

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Detailed Description

XLRP is a genetic (inherited) eye disease that affects cells in the retina (the lining of the back of the eye that detects light). It causes night blindness and gradual worsening of your vision.

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Conditions

X-Linked Retinitis Pigmentosa (XLRP)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Participants undergo pars plana vitrectomy and receive a central subretinal administration both eyes

On Day 1, participants will undergo a pars plana vitrectomy and receive a central subretinal administration of laruparetigene zovaparvovec in their first treated study eye.

For the first six participants, participants will undergo a pars plana vitrectomy followed by a central subretinal administration of laruparetigene zovaparvovec in their second eye between 30 and 60 days after the first surgery.

Once the first six study participants have been dosed in both eyes, the interval between dosing of the first and second eye may be reduced to a minimum of 7 days (and up to 14 days) for up to four of the remaining participants enrolled in the study, provided the following conditions are met:

• No unexpected safety concerns were observed following dosing of the first eye.
• An independent safety review by the Sponsor, Investigator, and DSMC Chair confirms that bilateral dosing may proceed.

Group Type: EXPERIMENTAL

Adeno-associated virus vector expressing a human RPGR gene

Intervention Type: BIOLOGICAL

Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501

Interventions

Adeno-associated virus vector expressing a human RPGR gene

Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Provide written informed consent or assent (per local regulation) prior to the conduct of any study-related procedures. Participants who provide assent must have a parent, guardian, or legal representative provide written informed consent.
• Be between 12 and 50 years of age (inclusive) at the time of providing informed consent and assent (as applicable)
• Be male (XY chromosome) and have at least 1 documented pathogenic or likely pathogenic variant in the RPGR gene, within exons 1-14 and/or ORF15, from an appropriately certified or accredited laboratory
• Have a clinical diagnosis of XLRP
• Be in good general health to withstand subretinal surgery and perioperative medications based on a complete physical examination and results from hematology, chemistry, and coagulation analyses performed at screening
• Be able and willing, as assessed by the Investigator, to follow study instructions, complete study assessments, comply with the protocol, and attend all study visits
• If the participant has a parent or caregiver, the parent or caregiver must be able to follow study instructions, comply with the protocol, and attend study visits with the participant, as required

• Have a BCVA ≤ 78 letters (approximately Snellen, 20/32) and ≥ 34 letters (approximately Snellen, 20/200) in each eye based on an ETDRS chart at each screening visit. The ETDRS letter score is the main visual acuity inclusion criterion for participants. Participants unable to read the ETDRS letters may use a tumbling "E" chart for the BCVA assessments
• Have an LLVA ≤ 64 letters (approximately Snellen, 20/50) in both eyes based on an ETDRS chart at each screening visit. Participants unable to read the ETDRS letters may use a tumbling "E" chart for the LLVA assessments
• Have an LLD of >10 letters
• Be able to perform all tests of visual and retinal function and structure in both eyes based on the participant's reliability and fixation, per the Investigator's discretion
• Have a detectable mean macular sensitivity by MAIA microperimetry at baseline between 1 and 12 dB in both eyes, as determined by the Investigator and confirmed by the central reading center (CRC), with a fixation loss ≤ 20% at each screening visit
• Have a detectable sub-foveal EZ line as assessed by SD-OCT in both eyes as confirmed by the CRC

Exclusion Criteria

• Have other known disease-causing mutations documented in the participant's medical history or identified through a retinal dystrophy gene panel that, in the opinion of the Investigator, would interfere with the potential therapeutic effect of the study drug or the quality of the assessments
• For participants with herpes simplex virus (HSV):

1. Have a history of oral or genital herpes and be unable and/or unwilling to use a prophylactic antiviral medication.

2. Have a history of ocular herpes.

3. Have active oral or genital herpes or are currently receiving treatment for active HSV infection

• Have complicating systemic diseases (e.g., medical conditions causing immunosuppression, autoimmunity, active systemic infection) that would preclude the gene transfer or ocular surgery if not adequately managed or treated
• Have a known sensitivity or allergy to systemic corticosteroids or other immunosuppressive medications
• Have used anticoagulant agents that may alter coagulation (e.g., warfarin, heparin, apixaban, or high-dose docosahexaenoic acid [fish oil]) within 7 days prior to study drug administration (ibuprofen, aspirin, or similar agents are acceptable
• Have received any vaccination/immunization within 60 days prior to Day 1 and/or during screening with the exception of the influenza vaccine, which is only exclusionary if received within 28 days prior to Day 1
• Have used systemic corticosteroids or other immunosuppressive medications within 3 months prior to study drug administration. Corticosteroids used on an as-needed basis administered by insufflation, inhalation, or local administration to the skin and mucosa such as Symbicort® (budesonide/formoterol), Flonase® (fluticasone propionate), and skin creams and ointments containing corticosteroids shall not be exclusionary
• If sexually active or planning to become sexually active, are unwilling to use barrier contraception for 3 months following study drug administration
• Have any other condition or reason that, in the opinion of the Investigator, would prevent the participant from completing all study assessments
• Have any other condition or reason that, in the opinion of the Investigator, makes the participant unsuitable for the study
• Are currently participating or recently participated in any other research protocol involving investigational agents or therapies that, in the opinion of the Investigator, would make the participant unsuitable for the study. Recent participation is defined as participation within 90 days of initial screening for this study OR within 10 half-lives of the investigational drug, whichever is longer
• Have previously received any adeno-associated virus (AAV) gene therapy product, stem cell therapy, cell-based therapy, or similar biologics

• Have pre-existing eye conditions in either eye that would preclude the planned surgery, interfere with the interpretation of study endpoints, or increase the risk of surgical complications (e.g., corneal opacities, diabetic retinopathy, retinal vasculitis, glaucoma, active cystoid macular edema)
• Have significant media opacity impacting evaluation of the retina or vitreous in either eye. This includes cataracts considered to be a major contributor to reducing visual acuity and/or if the participant is likely to require cataract extraction within 3 months of study drug administration
• Had intraocular surgery in either eye within the 90 days prior to the planned administration of study drug
• Have any active ocular/intraocular infection or inflammation (e.g., severe blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis, idiopathic or autoimmune-associated uveitis, or herpetic lesions) in either eye
• Have a history of corticosteroid-induced raised intraocular pressure (IOP) of > 25 mmHg following corticosteroid exposure in either eye, despite topical IOP-lowering pharmacologic therapy
• Have any artificial retinal implant or prosthesis in either eye
• Have an absence of clear ocular media and/or inadequate pupil dilation to facilitate good quality SD-OCT images in either eye.
• Have any history of rhegmatogenous retinal detachment in either eye
• Have myopia (spherical equivalent) exceeding -10 diopters Investigator or the presence of pathologic myopia in either eye.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Beacon Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

None None

Role: PRINCIPAL_INVESTIGATOR

Locations

University of Florida Jacksonville Ophthalmology

Jacksonville, Florida, United States

Site Status: RECRUITING

Bascom Palmer Eye Institute

Miami, Florida, United States

Site Status: NOT_YET_RECRUITING

Duke Eye Center

Durham, North Carolina, United States

Site Status: NOT_YET_RECRUITING

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Site Status: RECRUITING

OHSU Casey Eye Institute

Portland, Oregon, United States

Site Status: NOT_YET_RECRUITING

Retina Foundation of the Southwest

Dallas, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Serva Health Serva Health

Role: CONTACT

ProviderSupport@scenictrials.com

855-467-2364

Amy Christenson

Role: CONTACT

medical@beacontx.com

Facility Contacts

Shabbir Hamdani

Role: primary

shabbir.hamdani@ufhealth.org

904-244-9305

Adriana Drada

Role: primary

apd86@med.miami.edu

305-326-6000

Carol White

Role: primary

carol.white302@duke.edu

919-613-5078

Keyle Conrad

Role: primary

kconrad@cvphealth.com

513-569-3462

Hardew Mahto

Role: primary

mahto@ohsu.edu

503-494-2363

Kirsten Locke

Role: primary

kglocke@retinafoundation.org

214-363-3911 ext. 114

Other Identifiers

RPGR-005 Landscape

Identifier Type: -

Identifier Source: org_study_id